Potential impact of 5 years of ivermectin mass drug administration on malaria outcomes in high burden countries

Simple item page
dc.contributor.authorMarathe, Achlaen
dc.contributor.authorShi, Ruodingen
dc.contributor.authorMendez-Lopez, Anaen
dc.contributor.authorHu, Zhihaoen
dc.contributor.authorLewis, Bryan L.en
dc.contributor.authorRabinovich, Reginaen
dc.contributor.authorChaccour, Carlos J.en
dc.contributor.authorRist, Cassidyen
dc.date.accessioned2021-12-14T18:00:11Zen
dc.date.available2021-12-14T18:00:11Zen
dc.date.issued2021-11en
dc.description.abstractIntroduction The global progress against malaria has slowed significantly since 2017. As the current malaria control tools seem insufficient to get the trend back on track, several clinical trials are investigating ivermectin mass drug administration (iMDA) as a potential additional vector control tool; however, the health impacts and cost-effectiveness of this new strategy remain unclear. Methods We developed an analytical tool based on a full factorial experimental design to assess the potential impact of iMDA in nine high burden sub-Saharan African countries. The simulated iMDA regimen was assumed to be delivered monthly to the targeted population for 3 months each year from 2023 to 2027. A broad set of parameters of ivermectin efficacy, uptake levels and global intervention scenarios were used to predict averted malaria cases and deaths. We then explored the potential averted treatment costs, expected implementation costs and cost-effectiveness ratios under different scenarios. Results In the scenario where coverage of malaria interventions was maintained at 2018 levels, we found that iMDA in these nine countries has the potential to reverse the predicted growth of malaria burden by averting 20-50 million cases and 36 000-90 000 deaths with an assumed efficacy of 20%. If iMDA has an efficacy of 40%, we predict between 40-99 million cases and 73 000-179 000 deaths will be averted with an estimated net cost per case averted between US$2 and US$7, and net cost per death averted between US$1460 and US$4374. Conclusion This study measures the potential of iMDA to reverse the increasing number of malaria cases for several sub-Saharan African countries. With additional efficacy information from ongoing clinical trials and country-level modifications, our analytical tool can help determine the appropriate uptake strategies of iMDA by calculating potential marginal gains and costs under different scenarios.en
dc.description.notesThis study was funded by Unitaid (https://unitaid.org/project/mass-distribution-of-a).en
dc.description.sponsorshipUnitaiden
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1136/bmjgh-2021-006424en
dc.identifier.issn2059-7908en
dc.identifier.issue11en
dc.identifier.othere006424en
dc.identifier.pmid34764146en
dc.identifier.urihttp://hdl.handle.net/10919/106987en
dc.identifier.volume6en
dc.language.isoenen
dc.rightsCreative Commons Attribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectmalariaen
dc.subjecthealth economicsen
dc.titlePotential impact of 5 years of ivermectin mass drug administration on malaria outcomes in high burden countriesen
dc.title.serialBMJ Global Healthen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
e006424.full-1.pdf
Size:
1.69 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Scholarly Works, Population Health Sciences
Destination Area: Global Systems Science (GSS)
Scholarly Works, Statistics